Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (1-10 of 208) with videos related to

Pageof 21
Sort By:
Cancer|April 30, 2009
Combination targeted therapy in advanced renal cell carcinomaJeffrey Sosman, Igor Puzanov
Future Oncology (London, England)|June 1, 2012
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitorSamit Patrawala, Igor Puzanov
Biochemical Pharmacology|April 13, 2010
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinomaKeith T Flaherty, Igor Puzanov
Seminars in Cutaneous Medicine and Surgery|November 6, 2010
Targeted molecular therapy in melanomaIgor Puzanov, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Molecular targets in melanoma from angiogenesis to apoptosisJeffrey A Sosman, Igor Puzanov
Current Treatment Options in Oncology|March 23, 2015
Treatment of NRAS-mutant melanomaDouglas B Johnson, Igor Puzanov
The Journal of Community and Supportive Oncology|February 13, 2016
Thyroid nodule: not as clear-cut as it seemsGilbert Bader, Igor Puzanov, Kanishka Chakraborty
The Oncologist|March 13, 2020
Intratumoral Immunotherapy-Update 2019Omid Hamid, Rubina Ismail, Igor Puzanov
Current Oncology Reports|April 29, 2010
B-RAF inhibitors: an evolving role in the therapy of malignant melanomaCynthia Shepherd, Igor Puzanov, Jeffrey A Sosman
Molecular Oncology|March 12, 2011
Biological challenges of BRAF inhibitor therapyIgor Puzanov, Patrick Burnett, Keith T Flaherty
Pageof 21

Showing results (1-10 of 208) with videos related to

Sort By:
Pageof 21
Cancer|April 30, 2009
Combination targeted therapy in advanced renal cell carcinomaJeffrey Sosman, Igor Puzanov
Future Oncology (London, England)|June 1, 2012
Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitorSamit Patrawala, Igor Puzanov
Biochemical Pharmacology|April 13, 2010
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinomaKeith T Flaherty, Igor Puzanov
Seminars in Cutaneous Medicine and Surgery|November 6, 2010
Targeted molecular therapy in melanomaIgor Puzanov, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Molecular targets in melanoma from angiogenesis to apoptosisJeffrey A Sosman, Igor Puzanov
Current Treatment Options in Oncology|March 23, 2015
Treatment of NRAS-mutant melanomaDouglas B Johnson, Igor Puzanov
The Journal of Community and Supportive Oncology|February 13, 2016
Thyroid nodule: not as clear-cut as it seemsGilbert Bader, Igor Puzanov, Kanishka Chakraborty
The Oncologist|March 13, 2020
Intratumoral Immunotherapy-Update 2019Omid Hamid, Rubina Ismail, Igor Puzanov
Current Oncology Reports|April 29, 2010
B-RAF inhibitors: an evolving role in the therapy of malignant melanomaCynthia Shepherd, Igor Puzanov, Jeffrey A Sosman
Molecular Oncology|March 12, 2011
Biological challenges of BRAF inhibitor therapyIgor Puzanov, Patrick Burnett, Keith T Flaherty
Pageof 21